Sunbelt Securities Inc. Has $547,000 Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Sunbelt Securities Inc. increased its stake in Bristol-Myers Squibb (NYSE:BMY) by 19.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,080 shares of the biopharmaceutical company’s stock after acquiring an additional 1,614 shares during the quarter. Sunbelt Securities Inc.’s holdings in Bristol-Myers Squibb were worth $547,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the stock. Eagle Rock Investment Company LLC lifted its position in shares of Bristol-Myers Squibb by 32.1% in the 1st quarter. Eagle Rock Investment Company LLC now owns 64,927 shares of the biopharmaceutical company’s stock worth $3,521,000 after purchasing an additional 15,778 shares during the period. F&V Capital Management LLC lifted its holdings in Bristol-Myers Squibb by 2.9% in the first quarter. F&V Capital Management LLC now owns 158,308 shares of the biopharmaceutical company’s stock valued at $8,585,000 after buying an additional 4,485 shares during the period. TB Alternative Assets Ltd. bought a new stake in Bristol-Myers Squibb during the first quarter valued at $10,550,000. First Bancorp Inc ME grew its holdings in Bristol-Myers Squibb by 15.7% during the 1st quarter. First Bancorp Inc ME now owns 5,923 shares of the biopharmaceutical company’s stock worth $321,000 after acquiring an additional 805 shares during the period. Finally, Prentice Wealth Management LLC raised its position in shares of Bristol-Myers Squibb by 11.7% in the 1st quarter. Prentice Wealth Management LLC now owns 7,251 shares of the biopharmaceutical company’s stock worth $393,000 after acquiring an additional 757 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. BMO Capital Markets dropped their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research report on Friday, April 26th. Barclays reduced their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. StockNews.com lowered shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a report on Thursday. Finally, Wells Fargo & Company raised their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a research note on Thursday, April 18th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have given a buy rating to the company. According to MarketBeat, Bristol-Myers Squibb has an average rating of “Hold” and a consensus price target of $60.00.

Bristol-Myers Squibb Trading Up 0.7 %

Shares of Bristol-Myers Squibb stock opened at $42.50 on Thursday. The company has a market capitalization of $86.15 billion, a P/E ratio of -13.71, a price-to-earnings-growth ratio of 14.28 and a beta of 0.43. The stock has a fifty day simple moving average of $43.36 and a 200 day simple moving average of $48.31. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The firm had revenue of $11.87 billion during the quarter, compared to analyst estimates of $11.45 billion. During the same quarter in the prior year, the business posted $2.05 EPS. The business’s revenue was up 4.7% compared to the same quarter last year. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.59 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date of this dividend is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.65%. Bristol-Myers Squibb’s dividend payout ratio is currently -77.42%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.